Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Alphamab Oncology ( (HK:9966) ) just unveiled an update.
Alphamab Oncology announced its interim results for the first half of 2025, reporting a significant increase in revenue and a return to profitability compared to the same period in 2024. The company achieved several milestones in its clinical trials, including the publication of results for phase II studies and the initiation of phase III trials for its promising cancer treatments. These advancements are expected to strengthen Alphamab’s position in the oncology market and potentially offer new treatment options for patients with HER2-positive and other types of cancer.
The most recent analyst rating on (HK:9966) stock is a Hold with a HK$11.50 price target. To see the full list of analyst forecasts on Alphamab Oncology stock, see the HK:9966 Stock Forecast page.
More about Alphamab Oncology
Alphamab Oncology is a biopharmaceutical company focused on the development and commercialization of innovative biologics for the treatment of cancer. The company is engaged in advancing its drug pipeline with a focus on novel therapies for various types of cancer, including breast cancer, lung cancer, and ovarian cancer.
Average Trading Volume: 4,323,879
Technical Sentiment Signal: Buy
Current Market Cap: HK$9.98B
For a thorough assessment of 9966 stock, go to TipRanks’ Stock Analysis page.